Surfaces of biocompatible alloys used as implants play a significant role in their osseointegration. Surface sol-gel processing (SSP), a variant of the bulk sol-gel technique, is a relatively new process to prepare bioreactive nanostructured titanium oxide for thin film coatings. The surface topography, roughness, and composition of sol-gel processed Ti6Al4V titanium alloy coatings was investigated by atomic force microscopy (AFM) and X-ray electron spectroscopy (XPS). This was correlated with corrosion properties, adhesive strength, and bioreactivity in simulated body fluids (SBF). Electroimpedance spectroscopy (EIS) and polarization studies indicated similar advantageous corrosion properties between sol-gel coated and uncoated Ti6Al4V, which was attributed to the stable TiO2 composition, topography, and adhesive strength of the sol-gel coating. In addition, inductive coupled plasma (ICP) and scanning electron microscopy with energy dispersive spectrometry (SEM-EDS) analysis of substrates immersed in SBF revealed higher deposition of calcium and phosphate and low release rates of alloying elements from the sol-gel modified alloys. The equivalent corrosion behavior and the definite increase in nucleation of calcium apatite indicate the potential of the sol-gel coating for enhanced bioimplant applications.

THE first report dealing with the use of primidone (Mysoline) in the treatment of epilepsy was presented in 1952 by Handley and Stewart.1 Many other investigators2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 subsequently used this drug for the control of epileptic seizures. In 1953 Doyle and Livingston8 analyzed the results obtained in 100 patients with epilepsy who had been given primidone for periods of three months to one year. The purpose of the present paper is to report our findings in a larger group of patients who received this drug for a much longer period.Material for StudyThe drug was administered to 486 patients who . . .

S. K., a 26-month-old white male, was admitted to the hospital because of several generalized convulsions in the preceding hour. The mother had tuberculous pleurisy with effusion in 1938. The father had pulmonary tuberculosis with cavitation in 1933 for which pneumothorax was induced from 1934 to 1939 and a lobectomy performed in 1940. Since 1942 neither parent showed signs of active tuberculosis. The patient was one of twins born 3 weeks prematurely by breech presentation. Birth weight was 1,955 gm. He breathed and cried spontaneously. The neonatal period was eventful, development was entirely normal and there were no serious illnesses or convulsions. Because of the family history of tuberculosis, the patient and 3 siblings were vaccinated on June 18, 1954 with 1/16 ml. of Rosenthal's B.C.G. vaccine (dry freeze), intradermally. Tuberculin tests preceding vaccination were negative and became positive by September 11, 1954. Because the patient had a continuously draining ulcer at the site of vaccination and a large, tender, fluctuant axillary lymph node, treatment was started with streptomycin sulfate 250 mg. twice weekly and 50 mg. of isoniazid t.i.d. on August 4. On September 11, the streptomycin sulfate was reduced to 125 mg. twice weekly, but the isoniazid was continued at the original dosage. This regimen of therapy was maintained until admission to the hospital on November 1. About 1 hour before admission, the patient vomited several times while riding in the car with his mother. Shortly after this, the mother noted that ho seemed less alert and responsive than usual. He then had 3 generalized clonic convulsions in rapid succession, following which he became unconscious. He was brought immediately to the hospital.

The occurrence of hypertrichosis insixteen epileptic patients treated with Dilantin is reported.